A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Brenda LaTowsky, MD
Investigate MD
Principal Investigator - Brian Jiang, MD
University of California, San Diego
Principal Investigator - David Goldberg
Schweiger Dermatology Group
Principal Investigator - Edward Primka, MD
Dermatology Associates of Knoxville
Principal Investigator - Girish Munavalli, MD
Dermatology, Laser and Vein Specialists of the Carolinas
Principal Investigator - Kenneth Beer, MD
Research Institute of the Southeast LLC
Principal Investigator - Mark Ling, MD
Medaphase Inc
Principal Investigator - Megan Couvillion, MD
SBA Dermatology
Principal Investigator - Michael Gold, MD
Tennessee Clinical Research
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Investigate Md
Scottsdale, Arizona, United States
- Center for Clinical and Cosmetic Research
Aventura, Florida, United States
- Research Institute of the Southeast Llc
West Palm Beach, Florida, United States
- Dermatology, Laser and Vein Specialists of the Carolinas
Charlotte, North Carolina, United States
- Dermatology Associates of Knoxville
Knoxville, Tennessee, United States
- Tennessee Clinical Research
Nashville, Tennessee, United States
- Austin Institute for Clinical Research
Pflugerville, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 18 May 2021
- Primary completion
- 24 Aug 2022
- Completion
- 6 Dec 2022
- Last update posted
- 18 Mar 2024
- Registered enrollment
- 44
- Registry id
- NCT04844983
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.